Citations 0
Editor's Correspondence
April 28, 2003

Low-Molecular-Weight Heparin for Anticoagulation During Continuous Venovenous Hemofiltration

Author Affiliations

Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003

Arch Intern Med. 2003;163(8):981. doi:10.1001/archinte.163.8.981-a

We read with interest the recent report by Nagge and colleagues1 titled "Is Impaired Renal Function a Contraindication to the Use of Low-Molecular-Weight Heparin?" in the December 2002 issue of the ARCHIVES. We have used dalteparin as our anticoagulant of choice for critically ill patients requiring continuous venovenous hemofiltration for the last year (all with creatinine clearance <30 mL/min). Due to lack of available dosing data and potential benefits of dalteparin, we recently reported our experience in 52 consecutive patients to the Intensive Care Society of Great Britain (abstract to be published in the British Journal of Anaesthesia). This is, to our knowledge, the largest series in which fractionated heparin has been used in critically ill patients.

First Page Preview View Large
First page PDF preview
First page PDF preview